Zileuton
Links shared publicly online about this topic
FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)
drugs.com — “FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)” View full resource at drugs.com
Most Recently Shared on June 13, 2009 at 1:40 am By:
FDA Alert - Leukotriene Inhibitors for Asthma Get 'Precaution' Labeling for Possible Neuropsychiatric Events - http://bit.ly/9q3LW
FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)
drugs.com — “FDA Alert: Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)” View full resource at drugs.com
Most Recently Shared on August 29, 2009 at 7:07 pm By:
FDA Alert - Update on Leukotriene Inhibitors: Precaution Labeling for Possible Neuropsychiatric Events - http://bit.ly/SjR6o
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on June 7, 2010 at 3:35 pm By:
Internal Medicine Medical School
RT @JanCernyMDPhD New study targeting CML stem cells: http://clinicaltrials.gov/ct2/show/NCT01130688
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on August 4, 2011 at 3:49 pm By:
JanCerny, MD, PhD Hematologist, Physician, Doctor, PhD, Internist, and Oncologist
Clinical study in CML opened. http://ow.ly/5VdTa
Asthma Drugs Get 'Precaution' Labeling for Possible Psychiatric Side Effects - m
myoptumhealth.com — “Read the news article Asthma Drugs Get 'Precaution' Labeling for Possible Psychiatric Side Effects at www.myOptumHealth.com” View full resource at myoptumhealth.com
Most Recently Shared on June 13, 2009 at 2:22 am By:
Asthma Drugs Get 'Precaution' Labeling for Possible Psychiatric Side Effects: FDA says users of Singulair and si.. http://tinyurl.com/lhm679
Asthma drug shows promise for Alzheimer's, researchers say - McKnight's Long Term Care News
mcknights.com — “The asthma drug Zileuton (5-lipoxygenase) has demonstrated that it can reduce the formation of beta amyloid, the peptide in the brain linked to the development of Alzheimer's, according to researchers with the Temple University School of Medicine.” View full resource at mcknights.com
Most Recently Shared on March 28, 2011 at 4:14 pm By:
McKnight's LTC News Health News and Medical Publisher
Asthma drug shows promise for Alzheimer's, researchers say http://bit.ly/dO9qZk #healthcare
Leukotriene modifier drug label change requested by FDA - MPR
empr.com — “The FDA has requested that manufacturers of leukotriene modifiers include a precaution in the drug labeling regarding neuropsychiatric events that have been reported in some patients taking montelukast (Singulair, from Merck), zafirlukast (Accolate, from AstraZeneca) and zileuton (Zyflo CR from Cornerstone Therapeutics).” View full resource at empr.com
Most Recently Shared on June 16, 2009 at 6:39 pm By:
MPR News: Leukotriene modifier drug label change requested by FDA: The FDA has requested that manufactu.. http://tinyurl.com/nbs7rz
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Internal Medicine
The Department of Medicine at the University of Massachusetts Medical School (UMassMed, UMass). Account created by Carrie Saarinen, MEd. On hiatus Jan 2011.
Advertisement
